FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2750838424> ?p ?o ?g. }

• W2750838424 endingPage "51" @default.
• W2750838424 startingPage "35" @default.
• W2750838424 abstract "Aims This population pharmacokinetic analysis was conducted to describe quantitatively the regional differences and sources of interpatient variability on the apparent oral clearance of alisertib. Methods A population pharmacokinetic analysis was performed on data from 671 cancer patients in Western countries and in Japan/East Asia to whom alisertib 5–150 mg once or twice daily (b.i.d.) was administered in multiple dosing schedules. The final model was used to simulate alisertib pharmacokinetics in patients in the West and East Asian regions in the single‐agent schedule of 7 days of dosing in a 21‐day cycle. Exposure–safety relationships for mechanism‐related antiproliferative toxicities (neutropenia, mucositis and diarrhoea) were estimated by logistic regression. Results Alisertib pharmacokinetics were described by a two‐compartment model with four‐transit compartment absorption and linear elimination. The final model included a covariate effect of region on relative bioavailability, with patients in the East Asian region estimated to have a 52% higher bioavailability compared with Western patients. Population simulated exposure at 30 mg b.i.d. in patients in Asia was similar to that at 50 mg b.i.d. in Western patients [geometric mean (coefficient of variation) steady state area under the concentration‐time curve over the dosing interval (AUC (0–τ) ): 21.4 μM.h (52.3%) and 24.1 μM.h (53.6%), respectively]. Exposure–AE relationships could be described for neutropenia, stomatitis and diarrhoea, supporting the lower dosage of alisertib in Asia for global clinical development. Conclusions Model‐based simulations support the achievement of similar alisertib exposures in patients in Asia who are administered a 40% lower dose compared with the Western population, thereby providing a quantitative clinical pharmacology bridging and regional dosing rationale for global drug development." @default.
• W2750838424 created "2017-09-15" @default.
• W2750838424 creator A5010394649 @default.
• W2750838424 creator A5044490765 @default.
• W2750838424 creator A5059358587 @default.
• W2750838424 creator A5063496444 @default.
• W2750838424 creator A5076615111 @default.
• W2750838424 creator A5082894654 @default.
• W2750838424 creator A5086497754 @default.
• W2750838424 date "2017-11-24" @default.
• W2750838424 modified "2023-10-03" @default.
• W2750838424 title "Global population pharmacokinetics of the investigational Aurora A kinase inhibitor alisertib in cancer patients: rationale for lower dosage in Asia" @default.
• W2750838424 cites W1561129717 @default.
• W2750838424 cites W1930043322 @default.
• W2750838424 cites W1966606947 @default.
• W2750838424 cites W1973702452 @default.
• W2750838424 cites W1981073960 @default.
• W2750838424 cites W1981767989 @default.
• W2750838424 cites W1982959429 @default.
• W2750838424 cites W1985338536 @default.
• W2750838424 cites W1996506613 @default.
• W2750838424 cites W2023970099 @default.
• W2750838424 cites W2038619046 @default.
• W2750838424 cites W2043645215 @default.
• W2750838424 cites W2049320250 @default.
• W2750838424 cites W2055457865 @default.
• W2750838424 cites W2057466968 @default.
• W2750838424 cites W2062238374 @default.
• W2750838424 cites W2098801882 @default.
• W2750838424 cites W2100917151 @default.
• W2750838424 cites W2119421234 @default.
• W2750838424 cites W2136236608 @default.
• W2750838424 cites W2143265289 @default.
• W2750838424 cites W2152878394 @default.
• W2750838424 cites W2171285924 @default.
• W2750838424 cites W2171919275 @default.
• W2750838424 cites W2194756172 @default.
• W2750838424 cites W2196064518 @default.
• W2750838424 cites W2416271594 @default.
• W2750838424 cites W3145531923 @default.
• W2750838424 doi "https://doi.org/10.1111/bcp.13430" @default.
• W2750838424 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5736852" @default.
• W2750838424 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28891222" @default.
• W2750838424 hasPublicationYear "2017" @default.
• W2750838424 type Work @default.
• W2750838424 sameAs 2750838424 @default.
• W2750838424 citedByCount "12" @default.
• W2750838424 countsByYear W27508384242018 @default.
• W2750838424 countsByYear W27508384242019 @default.
• W2750838424 countsByYear W27508384242020 @default.
• W2750838424 countsByYear W27508384242021 @default.
• W2750838424 countsByYear W27508384242022 @default.
• W2750838424 countsByYear W27508384242023 @default.
• W2750838424 crossrefType "journal-article" @default.
• W2750838424 hasAuthorship W2750838424A5010394649 @default.
• W2750838424 hasAuthorship W2750838424A5044490765 @default.
• W2750838424 hasAuthorship W2750838424A5059358587 @default.
• W2750838424 hasAuthorship W2750838424A5063496444 @default.
• W2750838424 hasAuthorship W2750838424A5076615111 @default.
• W2750838424 hasAuthorship W2750838424A5082894654 @default.
• W2750838424 hasAuthorship W2750838424A5086497754 @default.
• W2750838424 hasBestOaLocation W27508384241 @default.
• W2750838424 hasConcept C112705442 @default.
• W2750838424 hasConcept C126322002 @default.
• W2750838424 hasConcept C181389837 @default.
• W2750838424 hasConcept C2777063308 @default.
• W2750838424 hasConcept C2777288759 @default.
• W2750838424 hasConcept C2778496288 @default.
• W2750838424 hasConcept C2908647359 @default.
• W2750838424 hasConcept C29730261 @default.
• W2750838424 hasConcept C71924100 @default.
• W2750838424 hasConcept C76318530 @default.
• W2750838424 hasConcept C98274493 @default.
• W2750838424 hasConcept C99454951 @default.
• W2750838424 hasConceptScore W2750838424C112705442 @default.
• W2750838424 hasConceptScore W2750838424C126322002 @default.
• W2750838424 hasConceptScore W2750838424C181389837 @default.
• W2750838424 hasConceptScore W2750838424C2777063308 @default.
• W2750838424 hasConceptScore W2750838424C2777288759 @default.
• W2750838424 hasConceptScore W2750838424C2778496288 @default.
• W2750838424 hasConceptScore W2750838424C2908647359 @default.
• W2750838424 hasConceptScore W2750838424C29730261 @default.
• W2750838424 hasConceptScore W2750838424C71924100 @default.
• W2750838424 hasConceptScore W2750838424C76318530 @default.
• W2750838424 hasConceptScore W2750838424C98274493 @default.
• W2750838424 hasConceptScore W2750838424C99454951 @default.
• W2750838424 hasIssue "1" @default.
• W2750838424 hasLocation W27508384241 @default.
• W2750838424 hasLocation W27508384242 @default.
• W2750838424 hasLocation W27508384243 @default.
• W2750838424 hasOpenAccess W2750838424 @default.
• W2750838424 hasPrimaryLocation W27508384241 @default.
• W2750838424 hasRelatedWork W1555144605 @default.
• W2750838424 hasRelatedWork W1970331292 @default.
• W2750838424 hasRelatedWork W2004325424 @default.
• W2750838424 hasRelatedWork W2080955156 @default.
• W2750838424 hasRelatedWork W2102649824 @default.
• W2750838424 hasRelatedWork W2379433997 @default.

• next